MA46855A - Inhibiteurs de magl - Google Patents

Inhibiteurs de magl

Info

Publication number
MA46855A
MA46855A MA046855A MA46855A MA46855A MA 46855 A MA46855 A MA 46855A MA 046855 A MA046855 A MA 046855A MA 46855 A MA46855 A MA 46855A MA 46855 A MA46855 A MA 46855A
Authority
MA
Morocco
Prior art keywords
magl inhibitors
magl
inhibitors
Prior art date
Application number
MA046855A
Other languages
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Michael B Shaghafi
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62145825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA46855A publication Critical patent/MA46855A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
MA046855A 2016-11-16 2017-11-15 Inhibiteurs de magl MA46855A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
MA46855A true MA46855A (fr) 2021-05-19

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046855A MA46855A (fr) 2016-11-16 2017-11-15 Inhibiteurs de magl

Country Status (27)

Country Link
US (2) US11059822B2 (fr)
EP (1) EP3541820B1 (fr)
JP (1) JP7042468B2 (fr)
KR (1) KR20190080935A (fr)
CN (1) CN110267962B (fr)
AU (1) AU2017361253B2 (fr)
BR (1) BR112019009880A2 (fr)
CA (1) CA3043617A1 (fr)
CL (1) CL2019001336A1 (fr)
CO (1) CO2019004945A2 (fr)
CR (1) CR20190239A (fr)
DO (1) DOP2019000118A (fr)
EA (1) EA038150B1 (fr)
EC (1) ECSP19034535A (fr)
ES (1) ES2952582T3 (fr)
IL (1) IL266547B (fr)
JO (1) JOP20190107A1 (fr)
MA (1) MA46855A (fr)
MX (1) MX2019005773A (fr)
NI (1) NI201900049A (fr)
PE (1) PE20191145A1 (fr)
PH (1) PH12019501079A1 (fr)
RU (1) RU2019115784A (fr)
TN (1) TN2019000149A1 (fr)
UA (1) UA125523C2 (fr)
WO (1) WO2018093949A1 (fr)
ZA (1) ZA201903099B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030020B2 (en) 2016-05-12 2018-07-24 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MA46867A (fr) 2016-11-16 2019-09-25 Abide Therapeutics Inc Formulations pharmaceutiques
LT3541807T (lt) 2016-11-16 2021-12-27 H. Lundbeck A/S Magl inhibitoriaus kristalinė forma
FI3630744T3 (fi) 2017-05-23 2023-03-21 H Lundbeck As MAGL:n pyratsoli-inhibiittoreita
MX2020002251A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
MX2020002254A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
CA3106510A1 (fr) * 2018-07-19 2020-01-23 Pfizer Inc. Composes spiro heterocycliques utilises en tant qu'inhibiteurs de magl
CA3175210A1 (fr) 2020-04-21 2021-10-28 Cheryl A. Grice Synthese d'un inhibiteur de monoacylglycerol lipase
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商H 朗德貝克公司 Magl抑制劑

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
CA2440803A1 (fr) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulateurs de l'activite du recepteur de la chimiokine
US20080255150A1 (en) 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
CA2716863A1 (fr) 2008-03-05 2009-09-11 Targacept, Inc. Amides de diazabicycloalkanes selectifs cibles sur un sous-type du recepteur de l'acetylcholine nicotinique
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (fr) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Modulateurs d'amide d'acide gras hydrolase de type diamine urée spirocyclique substituée par un groupe hétéroaryle
CN102575076B (zh) 2009-09-29 2014-08-20 普立万公司 具有模拟金属或珠光外观的聚酯制品
CN102781942B (zh) 2009-10-23 2015-09-23 詹森药业有限公司 用作食欲肽受体调节剂的二取代八氢吡咯并[3,4-c]吡咯
EP2542083B1 (fr) 2010-03-04 2015-05-06 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs de mglur2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (fr) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité
PT2800565T (pt) * 2012-01-06 2020-04-29 Scripps Research Inst Compostos de carbamato e processos para a sua preparação e utilização
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
IN2015DN00960A (fr) 2012-09-25 2015-06-12 Hoffmann La Roche
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
WO2015179559A2 (fr) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
CN107660199B (zh) 2015-03-18 2021-11-23 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
WO2017087854A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2017087858A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2017171100A1 (fr) 2016-03-31 2017-10-05 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US10030020B2 (en) 2016-05-12 2018-07-24 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
MA46867A (fr) 2016-11-16 2019-09-25 Abide Therapeutics Inc Formulations pharmaceutiques
LT3541807T (lt) 2016-11-16 2021-12-27 H. Lundbeck A/S Magl inhibitoriaus kristalinė forma
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110709084A (zh) 2017-03-13 2020-01-17 阿比德治疗公司 双重magl和faah抑制剂
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
FI3630744T3 (fi) 2017-05-23 2023-03-21 H Lundbeck As MAGL:n pyratsoli-inhibiittoreita
MX2020002251A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
MX2020002254A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商H 朗德貝克公司 Magl抑制劑

Also Published As

Publication number Publication date
RU2019115784A3 (fr) 2021-03-12
EA201991029A1 (ru) 2019-12-30
DOP2019000118A (es) 2019-09-30
CA3043617A1 (fr) 2018-05-24
ECSP19034535A (es) 2019-05-31
CN110267962A (zh) 2019-09-20
JP2020500178A (ja) 2020-01-09
CN110267962B (zh) 2022-04-01
NI201900049A (es) 2019-10-30
MX2019005773A (es) 2019-12-05
ES2952582T3 (es) 2023-11-02
EP3541820A4 (fr) 2020-06-10
IL266547B (en) 2022-06-01
NZ753471A (en) 2021-01-29
US11059822B2 (en) 2021-07-13
EP3541820A1 (fr) 2019-09-25
KR20190080935A (ko) 2019-07-08
US11691975B2 (en) 2023-07-04
AU2017361253A1 (en) 2019-05-30
JP7042468B2 (ja) 2022-03-28
UA125523C2 (uk) 2022-04-13
CL2019001336A1 (es) 2019-10-04
EA038150B1 (ru) 2021-07-14
TN2019000149A1 (en) 2020-10-05
CR20190239A (es) 2019-06-26
ZA201903099B (en) 2021-01-27
EP3541820C0 (fr) 2023-07-05
PH12019501079A1 (en) 2019-08-19
WO2018093949A1 (fr) 2018-05-24
PE20191145A1 (es) 2019-09-02
JOP20190107A1 (ar) 2019-05-09
CO2019004945A2 (es) 2019-05-21
US20200291023A1 (en) 2020-09-17
EP3541820B1 (fr) 2023-07-05
BR112019009880A2 (pt) 2019-08-13
RU2019115784A (ru) 2020-12-17
IL266547A (en) 2019-07-31
US20220135563A1 (en) 2022-05-05
AU2017361253B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
DK3405050T3 (da) Børnesikret snusbeholder
MA46857A (fr) Inhibiteurs de magl
MA46860A (fr) Inhibiteurs de magl
DK3442972T3 (da) Bromdomænehæmmere
MA46855A (fr) Inhibiteurs de magl
MA52635A (fr) Inhibiteurs de magl
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3445708T3 (da) Stigbøjle
DK3402792T3 (da) Quinolin-2-on-derivater
DK3335532T3 (da) Tandharve
DK3509963T3 (da) Pallecontainer
MA50406A (fr) Inhibiteurs pyrazole de magl
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
DE112017006386A5 (de) Schraubarbeitszylinder
MA46889A (fr) Inhibiteurs de gsk-3
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DE112017000734A5 (de) Glycolsensor
DK3471535T3 (da) Dyrelift
MA46888A (fr) Inhibiteurs de gsk-3
DK3323708T3 (da) Bovfender
DK3452590T3 (da) Plademagnet
DK3452587T3 (da) Penicillin-g-acylaser
DK3295800T3 (da) Sandwichkiksindretning